Differential expression of PD-L1 expression in high grade T1 (HGT1) v. muscle invasive urothelial carcinoma (MIUC) and its prognostic implications.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 4535-4535
Author(s):  
Stephanie A. Mullane ◽  
Lillian Werner ◽  
Anna Orsola ◽  
Jesse Novak ◽  
Toni K. Choueiri ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Differential Expression ◽  
High Grade ◽  
Prognostic Implications ◽  
Muscle Invasive

Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications

2017 ◽  
Vol 198 (4) ◽  
pp. 817-823 ◽  
Author(s):  
Stephanie A.M. Wankowicz ◽  
Lillian Werner ◽  
Anna Orsola ◽  
Jesse Novak ◽  
Michaela Bowden ◽  
...  
Keyword(s):  
Differential Expression ◽  
Bladder Carcinoma ◽  
High Grade ◽  
Prognostic Implications ◽  
Muscle Invasive

scholarly journals Recurrence and upstaging rates of T1 high-grade urothelial carcinoma of the bladder on repeat resection in a Canadian, resource-limited, healthcare system

2018 ◽  
Vol 12 (8) ◽  
Author(s):  
Adam Kinnaird ◽  
Peter Dromparis ◽  
Howard Evans
Keyword(s):  
Urothelial Carcinoma ◽  
Healthcare System ◽  
Bladder Tumour ◽  
Muscularis Propria ◽  
High Grade ◽  
Recurrence Rates ◽  
Repeat Resection ◽  
Resource Limited ◽  
Carcinoma Of The Bladder ◽  
Muscle Invasive

Introduction: Non-muscle-invasive bladder cancer is the most expensive malignancy to treat. Current Canadian guidelines recommend repeat transurethral resection of bladder tumour (TURBT) within six weeks after initial resection of T1 high-grade (T1HG) urothelial carcinoma, prior to initiation of intravesical bacillus Calmette- Guerin treatment. This is a burden on operating room usage and adds further cost and risk of complications. Internationally, major cancer centres report significant rates of recurrence and upstaging on repeat resection, however, minimal Canadian data is available. We aimed to determine the rate of recurrence and upstaging in a resource-limited, Canadian healthcare system.Methods: A retrospective review of patients receiving TURBT between November 2009 and November 2014 was performed. Patients were included if they had all three of the following: a pathological diagnosis of T1HG, adequate muscularis propria present in the specimen, and a repeat resection.Results: We reviewed 3166 patients who underwent TURBT and found 173 to meet our inclusion criteria. The overall recurrence and upstaging rates were 57.2% and 9.2%, respectively. Tumour recurrence and upstaging occurred more often in patients who had repeat resection after 12‒24 weeks compared to those patients whose repeat resection occurred within 12 weeks.Conclusions: Although recurrence rates are similar, we have found upstaging rates to be three- to four-fold lower than those previously reported. Despite this, one in 10 patients will be upstaged, justifying use of this resource within our healthcare system. Finally, timely repeat resection, within 12 weeks appears to be associated with preventing disease progression.

HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic implications

2002 ◽  
Vol 102 (5) ◽  
pp. 514-518 ◽  
Author(s):  
Stefan Krüger ◽  
Georg Weitsch ◽  
Hartwig Büttner ◽  
Arne Matthiensen ◽  
Torsten Böhmer ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Her2 Overexpression ◽  
Prognostic Implications ◽  
Carcinoma Of The Bladder ◽  
Muscle Invasive

scholarly journals Complications of radical cystectomy for bladder cancer

2018 ◽  
Vol 6 (12) ◽  
pp. 3898
Author(s):  
Maliikarjuna Gurram ◽  
Ravichander G. ◽  
Ravi Jahagidar ◽  
Vinay Reddy
Keyword(s):  
Bladder Cancer ◽  
Urothelial Carcinoma ◽  
Radical Cystectomy ◽  
Bladder Tumor ◽  
Invasive Bladder Cancer ◽  
Safe Procedure ◽  
High Grade ◽  
Early Complications ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

Background: Radical cystectomy with pelvic lymph node dissection is the standard treatment for muscle-invasive bladder cancer. With the advent of improved surgical techniques and postoperative management, the complications and mortality rates have reduced. The present study was done to analyse the perioperative, early and late compilations following radical cystectomy for bladder tumor.Methods: This is a prospective observational study of patients who underwent radical cystectomy for invasive bladder tumor from February 2016 to November 2017. Radical cystectomy was done through midline transperitoneal approach.  Urinary diversion was done by ileal conduit. All patients were followed at 6th week, 3rd month, 6th month, and at 1 year.Results: Total 21 patients underwent radical cystectomy, 17(80.95%) were males and 4 (19.04%) females. The median age was 60 years, ranging from 40 to 73 years. The   most common age group was 60 to 75 years (52.3%). Thirteen (61.9%) patients were smokers and all were males. Painless haematuria alone was most common presentation (of bladder tumor) seen in 15 (71.4%) patients. Early complications were seen in 8 (38.09%) patients, most common early complication was urinary leak 2 (9.5%) patents, other early complications were bowel leak, wound dehiscence, pelvic collection, burst abdomen, prolonged ileus, subacute intestinal obstruction, acute kidney injury and sepsis seen in one (4.25%) patient each. Late complications were seen in 4 (19.04%) patients.  Pelvic recurrence was the most common late complication seen in 2 (9.55%) patients. Ureteric stricture was seen in one patient (4.75%) for which percutaneous nephrostomy and antegrade DJ stenting was done. Among the histopathological variants of tumor 20 (95.25%) patients had high grade variants and only one (4.75%) had low grade papillary urothelial carcinoma. Among the high grade variants most common pathology was urothelial carcinoma in 17 (80.9%) patients.Conclusions: Radical cystectomy remains the main stay of treatment in muscle-invasive bladder cancer. This is relatively safe procedure with minimal morbidity and mortality.

scholarly journals Urothelial carcinoma with villoglandular differentiation (UCVGD) with small cell neuroendocrine carcinoma of urinary bladder

2019 ◽  
Vol 12 (1) ◽  
pp. bcr-2018-228017 ◽  
Author(s):  
Shilpy Jha ◽  
Suvradeep Mitra ◽  
Amit Kumar Adhya ◽  
Prasant Nayak
Keyword(s):  
Urinary Bladder ◽  
Urothelial Carcinoma ◽  
Male Patient ◽  
Neuroendocrine Carcinoma ◽  
Small Cell ◽  
High Grade ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Therapeutic Implications ◽  
Muscle Invasive ◽  
Aggressive Variant

Urothelial carcinoma with villoglandular differentiation (UCVGD) is a rare aggressive variant of urothelial carcinoma. It is usually associated with high-grade urothelial carcinoma or rarely adenocarcinoma. There is only one other previous report of UCVGD associated with small cell neuroendocrine carcinoma of urinary bladder. We report the second case of UCVGD with small cell neuroendocrine carcinoma of urinary bladder in a 74-year-old non-smoker male patient. The mass was muscle invasive and also invaded the prostate. This entity needs to be confidently diagnosed due to its prognostic and therapeutic implications.

Sign in / Sign up

Export Citation Format

Share Document